[Federal Register Volume 66, Number 147 (Tuesday, July 31, 2001)]
[Notices]
[Pages 39498-39499]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-18984]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Available for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Application Concerning Method and Compositions 
for Treating and Preventing Retinal Damage

AGENCY: U.S. Army Medical Research and Material Command, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the 
availability for licensing of U.S. Patent Application No. 09/590,174 
entitled ``Method and Compositions for Treating and Preventing Retinal 
Damage'' filed June 9, 2000. Foreign rights are also available (PCT/
US00/15812). This patent has been assigned to the Untied States 
Government as represented by the Secretary of the Army.

ADDRESSES: Commander, U.S. Army Medical Research and Material Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, Maryland 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Pual 
Mele, Office of Research & Technology Assessment, (301) 619-6664. Both 
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: This invention relates to the use of 
dihydrolipoci acid and alpha-lipoic acid to treat and prevent retinal 
damage arising from physical forces such as laser beams and to 
compositions containing phenyl nitrones and dihydrolipoic acids or 
alpha-lipoic acid as neuroprotective agents. The protective effect is 
believed to be due to the metabolites ability to protect neurons by a 
direct antioxidant effect, recycling of antioxidant vitamins E and C by 
redox, enhancement of glutathione, creation of at least 8 species of 
free radicals, and enhancement of intracellular ATP. Such may be useful 
in glaucoma, temporal arteritis, macular degeneration, diabetic 
retinopathy, proliferative retinopathy, retinitis pigmentosa and as an 
adjunctive

[[Page 39499]]

prophylactic therapy prior to or following cataract surgery.

Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 01-18984 Filed 7-30-01; 8:45 am]
BILLING CODE 3710-08-M